Mutual of America Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Mutual of America Capital Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-5,295	Closed	-$223K	–	1440
2024 Q4	$223K	Sell	5,295 -485	-8%	-$24.1K	﹤0.01%	1355
2024 Q3	$321K	Buy	+5,780	New	+$294K	﹤0.01%	1271
2022 Q2	–	Sell	-32,089	Closed	-$2.33M	–	1636
2022 Q1	$2.33M	Sell	32,089 -1,272	-4%	-$88.5K	0.02%	897
2021 Q4	$2.81M	Sell	33,361 -285	-0.8%	-$23.2K	0.03%	858
2021 Q3	$3.04M	Buy	33,646 +2,335	+7%	+$211K	0.03%	777
2021 Q2	$2.99M	Sell	31,311 -9,432	-23%	-$983K	0.03%	803
2021 Q1	$4.64M	Sell	40,743 -2,254	-5%	-$307K	0.05%	547
2020 Q4	$5.95M	Sell	42,997 -907	-2%	-$108K	0.07%	373
2020 Q3	$3.61M	Buy	43,904 +11,036	+34%	+$915K	0.05%	521
2020 Q2	$2.57M	Sell	32,868 -3,120	-9%	-$207K	0.04%	709
2020 Q1	$1.6M	Sell	35,988 -1,544	-4%	-$80.2K	0.03%	809
2019 Q4	$1.6M	Sell	37,532 -252	-0.7%	-$10.4K	0.02%	999
2019 Q3	$1.62M	Sell	37,784 -205	-0.5%	-$11.1K	0.02%	947
2019 Q2	$2.41M	Buy	37,989 +25	+0.1%	+$1.59K	0.03%	795
2019 Q1	$2.63M	Buy	37,964 +671	+2%	+$38.3K	0.04%	739
2018 Q4	$1.62M	Buy	37,293 +150	+0.4%	+$8.2K	0.03%	892
2018 Q3	$2.83M	Sell	37,143 -517	-1%	-$42.1K	0.04%	729
2018 Q2	$2.9M	Sell	37,660 -250	-0.7%	-$16.1K	0.04%	713
2018 Q1	$1.93M	Buy	37,910 +550	+1%	+$27.7K	0.03%	859
2017 Q4	$1.73M	Sell	37,360 -147	-0.4%	-$7.21K	0.03%	926
2017 Q3	$2M	Hold	37,507	–	–	0.03%	838
2017 Q2	$2.33M	Sell	37,507 -813	-2%	-$49K	0.04%	757
2017 Q1	$2.6M	Buy	38,320 +4,837	+14%	+$369K	0.05%	683
2016 Q4	$2.35M	Sell	33,483 -164	-0.5%	-$11.6K	0.04%	697
2016 Q3	$2.39M	Hold	33,647	–	–	0.05%	655
2016 Q2	$1.65M	Hold	33,647	–	–	0.04%	795
2016 Q1	$2.13M	Buy	33,647 +150	+0.4%	+$9.81K	0.05%	636
2015 Q4	$3.76M	Buy	33,497 +497	+2%	+$49.7K	0.08%	328
2015 Q3	$3.18M	Buy	33,000 +23,000	+230%	+$2.63M	0.08%	393
2015 Q2	$1.02M	Buy	+10,000	New	+$776K	0.02%	1003

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Mutual of America Capital Management's RARE Position: Q1 2025 in Review

Mutual of America Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2025, closing a stake of 5,295 shares — an estimated $223K sold.

Mutual of America Capital Management first reported a position in RARE in Q2 2015 and held it in 30 quarters. The position peaked at $5.95M in Q4 2020. 300 funds tracked by Wall St. Rank hold RARE as of Q1 2025.

Mutual of America Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q1 2025 after selling out during the quarter.
Mutual of America Capital Management sold 5,295 Ultragenyx Pharmaceutical shares in Q1 2025, an estimated $223K.
Mutual of America Capital Management first reported a position in Ultragenyx Pharmaceutical in Q2 2015 and held it in 30 quarters.
Mutual of America Capital Management's Ultragenyx Pharmaceutical position peaked at $5.95M in Q4 2020.
300 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2025.

Based on Mutual of America Capital Management's 13F filing for Q1 2025, filed 1 May 2025.